Le Lézard
Classified in: Health
Subject: SVY

Global Oncology Partnering Analysis 2014-2019 - Access to Over 3,500 Oncology Deal Records; Leading Oncology Deals by Value Since 2014


DUBLIN, Jan. 28, 2020 /PRNewswire/ -- The "Global Oncology Partnering 2014-2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Global Oncology Partnering 2014-2019 provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.

The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Oncology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Oncology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Oncology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Oncology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Oncology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Oncology partnering deals by specific Oncology target announced since 2014. The chapter is organized by specific Oncology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Oncology technologies and products.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all oncology partnering deals announced since 2014 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report Scope

This report is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

The available deals are listed by:

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report provides comprehensive access to available deals and contract documents for over 3,500 oncology deals. Analyzing actual contract agreements allows assessment of the following:

Key Topics Covered

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for Oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for Oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates

Chapter 4 - Leading Oncology deals and dealmakers
4.1. Introduction
4.2. Most active in Oncology partnering
4.3. List of most active dealmakers in Oncology
4.4. Top Oncology deals by value

Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Oncology therapeutic target

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/368s7u

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 03:05
To encourage balance, self-care and strength during this 2020 pandemic, Warriors Heart Clinical Director and U.S. Navy/Army Veteran Dr. Rick Boone encourages four resiliency steps. During a recent Newsmax interview, Dr. Boone emphasized, "What we're...

at 02:00
The Food Equity Initiative and Knoq, have created a "no-contact" specialty delivery service to deliver allergy-free foods to families in need during the Coronavirus outbreak. The COVID-19 pandemic is increasing food insecurity by interrupting income,...

9 avr 2020
Joe's Gluten-Free Foods is recalling Joe's Gluten-Free Foods brand Potato & Onion Perogies from the marketplace because they contain milk which is not declared on the label. People with an allergy to milk should not consume the recalled product...

9 avr 2020
Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced it launched the COVID-19 Clinical Trials Alliance to connect sites, sponsors and CROs to accelerate COVID-19 trials required...

9 avr 2020
There has been a lot of talk about ventilators and N95 masks, but CRIMADI has observed the reality is that healthcare workers are struggling with a much longer list of shortages every day. And feeling helpless in being able to save as many lives as...

9 avr 2020
The International Sleep Products Association (ISPA) today announced that US mattress manufacturing facilities across the country are working hard to produce and deliver mattresses and other critical products to fellow Americans in need. ...



News published on 28 january 2020 at 13:45 and distributed by: